Wolfgang A. Weber

发表

Molecular Design of 68Ga- and 89Zr-Labeled Anticalin Radioligands for PET-Imaging of PSMA-Positive Tumors.

M. Schwaiger, C. Decristoforo, A. Skerra, 2023, Molecular pharmaceutics.

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).

B. Hadaschik, M. Morris, F. Giesel, 2023, European urology.

Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.

M. Schwaiger, K. Becker, J. Siewert, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.

M. Retz, I. Rauscher, M. Eiber, 2023, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

M Schwaiger, H Graeff, M. Schwaiger, 1996, Journal of the National Cancer Institute.

The EANM practice guidelines for bone scintigraphy

F. Giammarile, K. Strobel, T. Kuwert, 2016, European Journal of Nuclear Medicine and Molecular Imaging.

Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer.

S. Reske, V. Drendel, C. Jilg, 2012, The Journal of urology.

Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET

M. Schwaiger, W. Weber, A. Stahl, 2004, European Journal of Nuclear Medicine and Molecular Imaging.

Reproducibility of metabolic measurements in malignant tumors using FDG PET.

M Schwaiger, M. Schwaiger, S. Ziegler, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.

M. Schwaiger, S. Ziegler, N. Avril, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

M. Schwaiger, N. Avril, F. Jänicke, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Quantitative assessment of tumor metabolism using FDG-PET imaging.

M Schwaiger, M. Schwaiger, N. Avril, 2000, Nuclear medicine and biology.

Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors.

D. Kinzel, M. Schwaiger, H. Feldmann, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis.

A. Drzezga, S. Minoshima, S. Noachtar, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery

H. Hricak, E. Sala, H. Vargas, 2015, European Radiology.

Correlation of the Genotype of Paragangliomas and Pheochromocytomas with Their Metabolic Phenotype on 3,4-Dihydroxy-6-18F-Fluoro-l-Phenylalanin PET

H. Rischke, M. Mix, W. Weber, 2012, The Journal of Nuclear Medicine.

The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy

S. Nekolla, I. Rauscher, M. Eiber, 2023, The Journal of Nuclear Medicine.

The importance of PET in the diagnosis and response evaluation of esophageal cancer.

J. Siewert, K. Ott, K Ott, 2006, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras.

H N Wagner, H Hines, A. Leung, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules

M. Schwaiger, S. Ziegler, W. Weber, 1998, The British journal of surgery.

Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice

E. Wagner, R. Glass, C. Spitzweg, 2023, Molecular therapy oncolytics.

Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17–21, 2014, Tübingen, Germany

R. Boellaard, B. Gückel, H. Hricak, 2015, Molecular Imaging and Biology.

Role of radionuclide imaging in trials of antiangiogenic therapy.

A. Alavi, F. Blankenberg, M. Graham, 2000, Academic radiology.

A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy

M. Hofman, A. Catafau, M. Seltzer, 2023, The Journal of Nuclear Medicine.

Reply: PSMA Is Not Specific to Prostate Cancer

S. Notohamiprodjo, M. Eiber, C. Lohrmann, 2023, The Journal of Nuclear Medicine.